ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $9,597,000 | -59.4% | 68,981 | -71.9% | 4.14% | -45.8% |
| Q3 2019 | $23,639,000 | -16.4% | 245,424 | 0.0% | 7.64% | -4.4% |
| Q2 2019 | $28,261,000 | -2.2% | 245,424 | 0.0% | 7.99% | -23.1% |
| Q1 2019 | $28,886,000 | +87.9% | 245,424 | 0.0% | 10.38% | +47.1% |
| Q4 2018 | $15,376,000 | -11.6% | 245,424 | 0.0% | 7.06% | +23.8% |
| Q3 2018 | $17,391,000 | -3.3% | 245,424 | -9.2% | 5.70% | -7.0% |
| Q2 2018 | $17,989,000 | -42.1% | 270,424 | -43.1% | 6.13% | -52.4% |
| Q1 2018 | $31,092,000 | +46.6% | 475,419 | -10.2% | 12.89% | -13.3% |
| Q4 2017 | $21,205,000 | – | 529,343 | – | 14.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |